Sign in

    Humana Inc (HUM)

    Q1 2024 Earnings Summary

    Reported on Jan 10, 2025 (Before Market Open)
    Pre-Earnings Price$327.98Last close (Apr 23, 2024)
    Post-Earnings Price$335.00Open (Apr 24, 2024)
    Price Change
    $7.02(+2.14%)

    What went well

    • Humana increased its individual Medicare Advantage (MA) membership growth target by 50,000 due to strong performance during the Open Enrollment Period (OEP), driven by competitive advantages, market share gains, and strong brand loyalty.
    • The company is committed to pricing discipline and margin recovery, aiming to achieve at least a 3% MA margin over time through multiyear pricing actions and productivity improvements, which will drive long-term shareholder value.
    • Humana believes in the strong core fundamentals and growth outlook for Medicare Advantage and value-based care, expecting mid-single-digit growth over the coming years, with its unique focus and expanding CenterWell capabilities positioning it well for future growth.

    Q&A Summary

    1. Margin Outlook and Recovery Timeline
      Q: What's your long-term margin target and recovery timeline?
      A: Humana reiterated its long-term margin target of 3% plus for individual Medicare Advantage (MA), acknowledging that recovering to this level will be a multiyear process due to funding, regulatory, and competitive environments. The company expects margin improvement to be slower than initially anticipated, especially in 2025, but sees more opportunity for recovery in 2026 and beyond as headwinds lessen.

    2. Impact of Final Rate Notice and TBC Thresholds
      Q: How does the final rate notice affect 2025 earnings and margins?
      A: The final rate notice requires larger benefit reductions to maintain stable margins, bringing Total Beneficiary Cost (TBC) thresholds into play. This limits the company's ability to price products profitably, potentially leading to plan and county exits. Humana needs more visibility into competitors' reactions before fully evaluating the impact on 2025 earnings, but acknowledges that net membership will be more impactful than previously thought.

    3. Medicare Advantage Membership Expectations
      Q: How will MA membership change in 2025?
      A: Humana anticipates membership declines in 2025 due to planned exits from certain plans and counties where TBC limits prevent profitable pricing. The extent of the decline will depend on competitive dynamics and the company's strategies to optimize benefits while maintaining margins.

    4. Utilization Trends and Cost Impacts
      Q: What are the current cost trends and utilization impacts?
      A: In the first quarter, inpatient utilization was in line with expectations after initial higher levels due to the 2-midnight rule changes. Training and adjustments have brought avoidance rates back in line, potentially providing a tailwind for the year. Non-inpatient trends and unit costs are still being evaluated due to limited claim visibility caused by data disruptions.

    5. Value Proposition of MA vs Traditional Medicare
      Q: How does MA's value proposition compare to Traditional Medicare in 2025?
      A: Despite headwinds, Humana believes MA continues to offer significant value over Traditional Medicare, providing about $2,400 annually in additional benefits such as care coordination, transportation, and dental services. While benefits may reduce slightly in 2025, the overall value proposition remains strong, supporting mid-single-digit growth expectations.

    6. Potential Market Exits
      Q: Are you planning market exits, and how many members could be affected?
      A: Humana is evaluating plan and county exits where TBC limits impede profitable pricing. While specifics are not disclosed for competitive reasons, the company will share more details post bid filing.

    7. Impact on CenterWell
      Q: How will membership changes affect CenterWell operations?
      A: The largest impact on CenterWell from membership changes will be on the pharmacy business due to its high penetration among Humana members. The primary care and home divisions are less affected, as they have contracts with other providers and payers, helping retain patients even if membership shifts.

    8. Standalone PDP Strategy and IRA Impacts
      Q: How are you approaching standalone PDP given IRA impacts?
      A: Humana is taking a cautious approach to its standalone Part D plans in 2025, focusing on risk mitigation due to significant changes from the Inflation Reduction Act. The company anticipates larger premium increases for some plans and aims to minimize inherent risks while assessing industry responses and reevaluating for 2026.

    9. CEO Transition and Operational Changes
      Q: Any operational changes with the CEO transition?
      A: No changes to the team have been made. The company is evaluating opportunities to drive efficiency and strengthen medical cost management, with plans to outline strategies by the end of the year.

    10. EPS Seasonality
      Q: What's driving EPS seasonality this year?
      A: The disproportionate earnings in the first half are due to a lower contribution from the MA insurance business compared to prior years. Factors include the impact of Prescription Drug Plan (PDP) seasonality and investment income. Administrative expenses show typical seasonality with no unusual patterns expected.

    Related Publications